logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

Compugen

Time to Remember Compugen The time has ripened for our readers and biotech investors to remember what we posted in the past years about Compugen ( CGEN ) . The importance of the reminder is that the firm has taken...

Read More

January 30, 2020

0

Illumina's COVIDSeq Test Granted Emergency Use Authorization. See Also: CRISPR Therapeutics and Vertex Encouraging News

Illumina Diagnostic Test COVIDSeq to Detect SARS-CoV-2 Illumina ( ILMN ) was issued an Emergency Use Authorization ( EUA ) from the FDA for the first COVID-19 diagnostic test utilizing next-generation sequence technology. The authorization was granted for the Illumina...

Read More

June 15, 2020

0

Good News for Four Companies: Jazz, Celldex, Inventiva & Illumina

Good News for Jazz, Celldex, Inventiva & Illumina Jazz Pharmaceuticals Good News Jazz Pharmaceuticals ( JAZZ ) announced along with its partner  PharmaMar (MSE: PHM ) that the U.S. FDA has approved Zepzelca™ (lurbinectedin) for adults with metastatic small cell lung cancer ( SCLC...

Read More

June 17, 2020

0

Vertex Beats Expectations in 2019 and Promises a Bright Future

Vertex Beats Expectations in 2019 Vertex ( VRTX ) reported fourth-quarter and full-year 2019 financial results yesterday. The results beat analysts’ expectations about the last quarter and the whole year 2019. In the same report the firm’s full-year financial guidance...

Read More

January 31, 2020

0

Gilead Stock Is Up 4%. See Also: Who Is Developing Prophylactic Vaccines for Coronavirus and Nektar's News That Moved the Stock Up Over 8%.

Gilead Stock Is UP Gilead Sciences' ( GILD ) provided its antiviral experimental drug remdesivir to physicians for a small number of patients infected with the 2019 novel coronavirus (2019-nCoV ) as a possible emergency savior. Gilead might have also...

Read More

February 3, 2020

0

Inovio Received $71 Million in Funding from the U.S. Department of Defense

Inovio Received US DoD Funding for CELLECTRA® 3PSP Smart Device Inovio ( INO ) announced today it has received $71 million in funding from the U.S. Department of Defense (DoD) to support the large-scale manufacture of the company's proprietary CELLECTRA®...

Read More

June 23, 2020

0

The COVID-19 Vaccines' Developing Firms' Bizarre Evaluations

Novel Coronavirus Vaccines and Wall Street Vaccines against novel coronavirus are recognized now as the only way to return disrupted human lives back to normal. Vaccines have become the most important topic for Wall Street’s investors and analysts especially at...

Read More

June 26, 2020

0

Exelixis Has Good News for Metastatic Castration-Resistant Prostate Cancer

Exelixis Announced Results from its CABOMETYX® Combination with Roche's TECENTRIQ® News announced by Exelixis ( EXEL ) about encouraging results from the combination of its product cabozantinib ( CABOMETYX® ) with Roche’s product atezolizumab ( TECENTRIQ® ) on metastatic castration-resistant...

Read More

February 11, 2020

0

We Are Not Yet in Bizarro World

Unclear Reasoning for the Inovio Selloff Though Inovio ( INO ) announced positive interim clinical data of INO-4800 (its vaccine candidate against novel coronavirus (SARS-CoV-2)) from the first of two Phase 1 clinical trial cohorts, the stock still fell around...

Read More

June 30, 2020

0

Prohost Biotech's Decision About Akero Therapeutics

Akero Therapeutics Today we posted good news from Akero Therapeutics ( AKRO ) under News & Comments . The news was about results from Phase 2a BALANCED study of the firm’s product efruxifermin (EFX), for patients with nonalcoholic steatohepatitis (...

Read More

July 1, 2020

0

  • Previous
  • 1
  • 2
  • ...
  • 4
  • 5
  • 6
  • ...
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy